CRISPR Gene Editing Shows Promise for Protecting Healthy Cells During Blood Cancer Treatment
Researchers are exploring how CRISPR gene editing might give doctors a more precise way to treat aggressive blood cancers while protecting the healthy cells patients need to survive after a transplant.
The approach involves removing a protein called CD33 from donor stem cells using CRISPR technology. Normally, CD33 serves as a target for certain cancer treatments designed to attack leukemia and other blood cancers. However, this targeting can also destroy healthy blood cells that patients require during recovery, leading to serious complications.
In a trial with 30 patients, the edited stem cells successfully engrafted after transplantation. These modified cells appeared to shield healthy blood cells from CD33-targeted therapies, allowing doctors to potentially attack cancer cells more aggressively while sparing the healthy cells that support patient recovery.
The technique represents a step toward what researchers describe as a "double-layer safety switch" — removing the target from healthy cells while leaving it present on cancer cells, enabling more selective treatment. Further studies with larger patient groups will be needed to confirm these preliminary findings and evaluate long-term outcomes.